(Q38432573)

English

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

scientific article published on 09 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase II clinical trial

0 references

squamous cell carcinoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Vassiliki Saloura

1

object named as

Vassiliki Saloura

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Salem Billan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Steen Lisby

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Thomas C Gauler

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

9 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

73

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1227-1239

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

https://scigraph.springernature.com/pub.10.1007/s00280-014-2459-z

0 references

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Interstitial lung disease associated with drug therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Targeting EGFR resistance networks in head and neck cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38432573&oldid=1797648425"